Reviewer's report

Title: Predictors of patient satisfaction with antipsychotic medication in schizophrenia: Data from a randomized double-blind trial

Version: 1 Date: 9 June 2006

Reviewer: PARELLADA EDUARD

Reviewer's report:

General
This is a nice and well done study. I believe that the topic of this manuscript is quite interesting and novel. The sample size is good, the statistics appear thorough, and overall, the paper is well presented.

The Ms give support that treatment satisfaction is positively related to symptom improvement, particularly positive symptoms. The Ms also suggest that patient satisfaction with antipsychotic treatment may be related to compliance, as those who were more satisfied remained in the trial for a longer time. The Ms is hypothesis driven due to the recent availability and research of long-acting atypical antipsychotics designed to improve compliance.

Major Compulsory Revisions (that the author must respond to before a decision on publication can be reached)

Minor Essential Revisions (such as missing labels on figures, or the wrong use of a term, which the author can be trusted to correct)

Discretionary Revisions (which the author can choose to ignore)

I believe that the present descriptive title of the Ms could be change to a more results focusing title so that the title reads as follows: Reduction in psychotic symptoms as a predictor of patient satisfaction with antipsychotic medication in schizophrenia: Data from a randomized double-blind trial.

What next?: Accept after discretionary revisions

Level of interest: An article of importance in its field

Quality of written English: Acceptable

Statistical review: No

Declaration of competing interests:
Dr Eduard Parellada has received research grants from Marató TV3 Foundation (registered number 012410), Janssen-Cilag, GlaxoSmithKline and Eli Lilly Company; is a consultant for Janssen-Cilag and GlaxoSmithKline; has received honoraria from Janssen-Cilag; and is a speaker/advisory board member for Janssen-Cilag